HDAC9 and central nervous system cancer: In a limited number of studies demonstrating the combination use of HDAC inhibitors (HDACi) with proteasome inhibitors in GB treatment [44–46], it has been reported that the co-administration of the proteasome inhibitor Bortezomib with HDACi molecules increases DNA damage and induces apoptosis in glioma cells.